InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $2.235 0.61 (37.54%)+
Announcement
Release
29 Jul 2026 8:45AM
Price at Release
$1.625
Full Release
download
Summary
PYC Therapeutics Limited, a clinical-stage biotechnology company based in Australia, released its Quarterly Activities and Appendix 4C Cash Flow Report for the quarter ending 30 June 2026. The company is advancing its precision medicine initiatives, targeting genetic diseases through RNA therapeutic approaches. Key developments include progress in clinical trials for Polycystic Kidney Disease (PKD), Phelan-McDermid Syndrome (PMS), and Retinitis Pigmentosa Type 11 (RP11). The company also received significant approvals from the Safety Review Committee (SRC) to escalate dosing in ongoing trials and obtained Orphan Drug Designation from the European Medicines Agency for its RP11 program. Financially, PYC maintains a solid cash position with $669 million on hand, focusing its expenditures on research and development. The report highlights the completion of enrolment in various clinical stages and upcoming presentations of clinical data to support further regulatory submissions.
Key Points
  • PYC is advancing precision medicines for genetic diseases.
  • Quarterly update includes significant progress in clinical trials for PKD, PMS, and RP11.
  • Received SRC approvals for dose escalation in trials and Orphan Drug Designation for RP11.
  • Strong financial position with $669 million cash reserves.
  • Focus on research and development expenditures.
  • Completion of enrolment in several clinical trials.
  • Upcoming data presentations to support regulatory submissions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.